IQVIA Holdings Inc. - IQV STOCK NEWS

IQVIA announced the appointment of Dr. Christina Mack as chief scientific officer for its Real World Solutions business, effective July 7, 2022. She succeeds Dr. Nancy Dreyer, who is retiring after nearly two decades with the company. Dr. Mack has extensive experience in real-world evidence, improving patient care. Prior to this role, she was vice president of Epidemiology and Clinical Evidence. Her strong educational background includes degrees from the University of Notre Dame and the University of North Carolina at Chapel Hill.

In 2021, oncology trial starts soared by 56% since 2016, with a record 30 novel active substances launched globally. Despite this progress, oncologists face 20-29% lower caseloads than pre-COVID-19, with over 30 million cancer screenings disrupted, risking timely diagnoses for more than 58,000 patients. Global oncology spending is projected to exceed $300 billion by 2026, while treated patients have increased by an average of 4% annually. The surge in R&D signifies a promising future for cancer treatments, although challenges from the pandemic linger.

IQVIA Holdings Inc. (NYSE:IQV) will have CFO Ron Bruehlman speak at the Jefferies Healthcare Conference in New York City on Friday, June 10, 2022, at 11:30 a.m. ET. A live audio webcast of the presentation will be accessible on the IQVIA Investor Relations website, with a replay available later that day. IQVIA is a global leader in advanced analytics, technology solutions, and clinical research services for life sciences, operating in over 100 countries with approximately 82,000 employees. The company emphasizes patient privacy and utilizes various technologies to enhance healthcare outcomes.

IQVIA Holdings Inc. reported strong first-quarter 2022 results with revenue reaching $3,568 million, a 4.7% year-over-year increase. GAAP net income surged 53.3% to $325 million, while GAAP diluted EPS rose 54.1% to $1.68. Adjusted EBITDA was $812 million, up 9.1%. The record R&D solutions bookings exceeded $1.9 billion, with a backlog over $25 billion. Full-year revenue guidance has been updated to $14,450 million to $14,750 million, reflecting a 4.2% to 6.3% reported growth. Despite macro challenges, adjustments to EBITDA and EPS guidance reaffirm expected growth.

In 2021, spending on medicines in the U.S. reached $407 billion, a 12% increase from 2020, driven largely by COVID-19 vaccines and therapeutics. Prescription drug use hit a record 194 billion daily doses, with overall drug spending expected to return to pre-pandemic growth by 2023. However, patient out-of-pocket costs rose $4 billion in 2021, reflecting ongoing economic pressures. The report indicates a shift towards biosimilars affecting branded drug sales and forecasts a 2.1% compound annual growth in medicine spending through 2026.

IQVIA Holdings Inc. will announce its first-quarter 2022 financial results on April 27, 2022, before the market opens. The management will host a conference call and webcast at 9:00 a.m. Eastern Time. Interested participants must register in advance to join the call and will receive details via email. A replay of the webcast will be accessible two hours post-event. IQVIA is a leading provider of analytics and clinical research services in the life sciences, operating in over 100 countries with about 79,000 employees.

IQVIA (NYSE:IQV) has secured a contract from the European Medicines Agency (EMA) to provide analytics services for the DARWIN EU® Coordination Centre, managed by Erasmus University Medical Center Rotterdam. This initiative aims to establish a pan-European network of real-world healthcare data systems, enhancing the regulatory decision-making process for drug safety and effectiveness. Over two years, IQVIA will contribute technical expertise and management for pharmacovigilance data, improving data standardization and accessibility for regulatory agencies.

IQVIA (NYSE:IQV) has launched OCE+, an upgrade to its customer engagement platform. This innovation introduces the Next Best recommendation engine, providing AI-driven suggestions to healthcare professionals (HCP) for optimized engagement. OCE+ aims to enhance productivity, the HCP experience, and return on investment (ROI). By integrating sophisticated data analytics and AI, it facilitates informed decision-making for life sciences teams, promoting better personalization and increased efficiency in customer interactions.

IQVIA Holdings Inc. (NYSE:IQV) announced the appointment of Costa Panagos as president of its Research & Development Solutions unit, succeeding Richard Staub III, who is retiring after over three decades. Panagos, with 25 years of industry experience, was previously the president of R&D Operations and CEO of Q2 Solutions. His effective date is April 1, 2022. Richard Staub will remain with the company as a senior advisor, aiding in business development and client management. This transition is expected to be quick and seamless, as per CEO Ari Bousbib.